Sökning: WFRF:(Fransson Moa) >
T-cell responses af...
T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis
-
- Burman, Joachim (författare)
- Uppsala universitet,Neurologi,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
-
- Fransson, Moa (författare)
- Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
-
- Tötterman, Thomas H. (författare)
- Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
-
visa fler...
-
- Fagius, Jan (författare)
- Uppsala universitet,Neurologi
-
- Mangsbo, Sara M. (författare)
- Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
-
- Loskog, Angelica S. I. (författare)
- Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab
-
visa färre...
-
(creator_code:org_t)
- 2013-09-12
- 2013
- Engelska.
-
Ingår i: Immunology. - : Wiley. - 0019-2805 .- 1365-2567. ; 140:2, s. 211-219
- Relaterad länk:
-
https://www.ncbi.nlm...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Autologous haematopoietic stem cell transplantation (HSCT) for relapsing-remitting multiple sclerosis is a potentially curative treatment, which can give rise to long-term disease remission. However, the mode of action is not yet fully understood. The aim of the study was to evaluate similarities and differences of the CD4(+) T-cell populations between HSCT-treated patients (n = 12) and healthy controls (n = 9). Phenotyping of memory T cells, regulatory T (Treg) cells and T helper type 1 (Th1) and type 17 (Th17) cells was performed. Further, T-cell reactivity to a tentative antigen, myelin oligodendrocyte glycoprotein, was investigated in these patient populations. Patients treated with natalizumab (n = 15) were included as a comparative group. White blood cells were analysed with flow cytometry and T-cell culture supernatants were analysed with magnetic bead panel immunoassays. HSCT-treated patients had similar levels of Treg cells and of Th1 and Th17 cells as healthy subjects, whereas natalizumab-treated patients had lower frequencies of Treg cells, and higher frequencies of Th1 and Th17 cells. Cells from HSCT-treated patients cultured with overlapping peptides from myelin oligodendrocyte glycoprotein produced more transforming growth factor-beta(1) than natalizumab-treated patients, which suggests a suppressive response. Conversely, T cells from natalizumab-treated patients cultured with those peptides produced more interleukin-17 (IL-17), IL-1 and IL-10, indicating a Th17 response. In conclusion, we demonstrate circumstantial evidence for the removal of autoreactive T-cell clones as well as development of tolerance after HSCT. These results parallel the long-term disease remission seen after HSCT.
Nyckelord
- haematopoietic stem cell transplantation
- multiple sclerosis
- natalizumab
- neuroimmunology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas